Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000010
Chunk: 5

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 5
---
 Kim        |     | Representative Director, President & Chief Executive Officer* |     | President, U.S. Business Unit and U.S. Country Head          |
| Christophe Weber |     | Retirement                                                    |     | Representative Director, President & Chief Executive Officer |

* Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting in June 2026.

2. Biography of Newly Appointed Representative Director

| Date of Birth |     | Business Experience                                                |     | Number of ADSs Held* |
| June 6, 1970  |     | June 2016    Joined Shire plc                                      
 June 2016    Head of International Value Demonstration & Access    
 May 2018    Head of Global Hematology Franchise                    
 January 2019    Joined Takeda Pharmaceutical Company Limited       
 January 2019    President, Plasma-Derived Therapies Business Unit  
 April 2022    President, U.S. Business Unit, and U.S. Country Head 
 (to present)                                                       |     | 95,065 ADSs          |

*There are no ordinary shares held as of the filing date.

3. Effective Date of Changes (planned)

June 2026